Less benefit from warfarin in diabetics after myocardial infarction?

Cardiology

Volumn 111, Issue 3, 2008, Pages 161-166

  Smith, Pål J ^a,b   Hurlen, Mette ^c   Abdelnoor, Michael ^c   Arnesen, Harald ^c  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Aspirin; Diabetes; Myocardial infarction; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTICOAGULANTS; ASPIRIN; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; SURVIVAL ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 52949107546     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000121598     Document Type: Article

References (21)

1. Smith P, Arnesen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152.
2. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
3. Anand SS, Yusuf S: Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-2067.
4. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE: Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-113.
5. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H: Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002;347:969-974.
6. Loeliger EA: The optimal therapeutic range in oral anticoagulation. History and proposal. Thromb Haemost 1979;42:1141-1152.
7. Kirkwood TB: Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983;49:238-244.
8. Smith P, Arnesen H, Abdelnoor M: Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction. Arch Intern Med 1992;152:993-997.
9. Nomenclature and criteria for diagnosis of ischemic heart disease: report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979;59:607-609.
10. Breslow NE, Day DN: Classical methods of analysis of grouped data; in Breslow NE, Day DN (eds): Statistical Methods in Cancer Research. The Analysis of Case-Control Studies. Lyon, World Health Organization, International Agency for Research on Cancer, 1980, pp 122-159.
11. Byar DP: Assessing apparent treatment - covariate interactions in randomized clinical trials. Stat Med 1985;4:255-263.
12. van Bergen PF, Deckers JW, Jonker JJ, van Domburg RT, Azar AJ, Hofman A: Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. Br Heart J 1995;74:117-121.
13. Johnson SG, Witt DM, Delate T, Sadler MA: An examination of the association between therapeutic anticoagulation control and glycemic control for patients with diabetes on oral anticoagulation therapy. J Thromb Thrombolysis 2005;19:209-212.
14. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986;35:250-253.
15. Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH: Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in type 2 diabetic men with and without coronary heart disease. Diabetologia 2004;47:1557-1565.
16. Taube J, McWilliam N, Luddington R, Byrne CD, Baglin T: Activated protein C resistance, effect of platelet activation, platelet derived microparticles, and atherogenic lipoproteins. Blood 1999;93:3792-3797.
17. Fattah MA, Shaheen MH, Mahfouz MH: Disturbances in haemostasis in diabetes mellitus. Dis Markers 2004;19:251-258.
18. Mustand JF, Packham MA: Platelets and diabetes mellitus. N Engl J Med 1984;311:665-667.
19. Lupu C, Calb M, Ionescu M, Lupu F: Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients. Thromb Haemost 1993;70:579-583.
20. Cohen Z, Gonzales RF, Davis-Gorman GF, Copeland Jack G, McDonagh PF: Thrombin activity and platelet microparticle formation are increased in type 2 diabetic patients: a potential correlation with caspase activation. Thromb Res 2002;107:217-221.
21. Halfon S, Malinowski J, Sinha U: Effect of anticoagulants and antiplatelet agents on platelet-mediated thrombin generation. Blood Coagul Fibrinolysis 2002;13:715-724.